NEW

The United States Department of Health and Human Services (HHS) Office of Inspector General (OIG) issued Advisory Opinion 24-02,…

During a United States House of Representatives Energy & Commerce subcommittee hearing, Health and Human Services (HHS)…

The Berkeley Research Group recently published an updated report that compared sales across federal prescription drug programs, to…

The California Hospital Association (“CHA”) filed a Complaint against Blue Cross of California d/b/a Anthem Blue Cross (“Anthem”),…

In March, the U.S. District Court for the District of Oregon issued a ruling in Pharmaceutical Research and Manufacturers of…

On April 4, 2024, the Centers for Medicare & Medicaid Services (“CMS”) issued the contract year 2025 Medicare Advantage and…

The Biden administration recently issued a rule making changes to the 340B drug discount program’s dispute resolution process. The…

Recently, the United States Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) research team…

The United States Department of Justice (DOJ) recently intervened in a False Claims Act case against Regeneron Pharmaceuticals…

With less than two weeks before the Connecticut reporting deadline for pharmaceutical companies to report representative…